TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Gross Profit Over TimeExpanding
Percentile Rank50
3Y CAGR-13.3%
Studio
Year-over-Year Change

Revenue minus cost of goods sold

3Y CAGR
-13.3%/yr
Annual compound
Percentile
P50
Within normal range
vs 3Y Ago
0.7x
Contraction
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$8.84M+213.7%
2024$2.82M-86.6%
2023$21.05M+55.5%
2022$13.54M+33.5%
2021$10.14M+152.0%
2020$-19.49M-106.4%
2019$-9.44M-